Cidofovir dihydrate

Overview

Cidofovir is an injectable antiviral medication for the treatment of cytomegalovirus (CMV) retinitis in patients with AIDS. It suppresses CMV replication by selective inhibition of viral DNA polymerase and therefore prevention of viral replication and transcription. It is an acyclic nucleoside phosphonate, and is therefore independent of phosphorylation by viral enzymes, unlike acyclovir. Cidofovir was discovered at the Institute of Organic Chemistry and Biochemistry, Prague, and developed by Gilead Sciences and is marketed with the brand name Vistide by Gilead in the USA, and by Pfizer elsewhere. Maintenance therapy with cidofovir involves an infusion only once every two weeks, making it a convenient treatment option. Because dosing is relatively infrequent, a permanent catheter is not necessary for infusions. Source summary: Cidofovir dihydrate for research use: antiviral nucleoside analog. Chemical reagent for biochemical studies, synthesis, and assay development.

Application

Products > Drug Discovery > Inhibitor | Products > Drug Discovery > Inhibitor | Infection | CMV

Product Information

• Catalog No.: B0084-084507
• CAS No.: 149394-66-1
• Molecular Formula: C8H18N3O8P
• Molecular Weight: 315.22
• Purity: >98%
• Storage: Store at RT
• Solubility: Soluble in DMSO

Source

Original product source